LAPSInsulin Combo

LAPSInsulin Combo (HM14220) is a once-weekly, fixed-dose combination biologic being developed by Hanmi Pharmaceutical for the treatment of type 2 diabetes mellitus. It consists of LAPSInsulin 115 (HM12470), a long-acting basal insulin analog, and efpeglenatide (LAPSCA-Exendin-4), a long-acting glucagon-like peptide-1 receptor (GLP-1R) agonist. Both components utilize Hanmi's proprietary LAPSCOVERY (Long-Acting Protein/Peptide Discovery) technology, which conjugates the active peptides to a non-glycosylated human immunoglobulin Fc fragment via a flexible PEG linker to extend their circulating half-lives. By combining a basal insulin with a GLP-1 receptor agonist, LAPSInsulin Combo aims to provide synergistic glycemic control and mitigate the risk of insulin-induced weight gain with the convenience of once-weekly subcutaneous administration. The asset was briefly licensed to Sanofi in 2015 as part of the Quantum Project, but development rights were returned to Hanmi in late 2016.

Other names

HM14220HM-14220HM 14220LAPS Insulin ComboLAPSInsulin/LAPSGLP-1 ComboLAPSInsulin/LAPSGLP-1 Combination